We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

A Single Oral Dose Study of ASP015K in Healthy Volunteers Assessing the Relative Bioavailability Across Three Tablet Strengths From a New Formulation of ASP015K

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01486017
Recruitment Status : Completed
First Posted : December 6, 2011
Last Update Posted : December 6, 2011
Information provided by (Responsible Party):

Study Description
Brief Summary:
The purpose of this study is to determine the relative bioavailability and pharmacokinetic profiles from three strengths of a new tablet formulation of ASP015K and to evaluate the safety and tolerability after a single dose of three different strengths of a new tablet formulation.

Condition or disease Intervention/treatment Phase
Bioavailability of ASP015K Pharmacokinetics of ASP015K Healthy Subjects Drug: ASP015K Phase 1

Detailed Description:
Eligible subjects will be admitted on Day-1 and remain confined on the unit for 16 days. Each subject will receive a single dose of study drug per the defined treatment periods on the mornings of Day 1, Day 6 and Day11. There will be a minimum of 5 days between each consecutive dose group. Any subject discontinuing the study prior to completion should have all end of study evaluations completed.

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Official Title: A Phase 1, Single-Dose, Open-Label, 3-Period, Randomized Crossover Study to Assess the Relative Bioavailability Across Three Strengths of a New ASP015K Tablet Formulation in Healthy Volunteers
Study Start Date : September 2011
Primary Completion Date : September 2011
Study Completion Date : September 2011
Arms and Interventions

Arm Intervention/treatment
Experimental: Treatment A
ASP015K oral dose low strength
Drug: ASP015K
Experimental: Treatment B
ASP015K oral dose medium strength
Drug: ASP015K
Experimental: Treatment C
ASP015K oral dose high strength
Drug: ASP015K

Outcome Measures

Primary Outcome Measures :
  1. Composite of pharmacokinetic parameters of ASP015K: Cmax, AUClast, and AUCinf [ Time Frame: Up to Day 15 ]

Secondary Outcome Measures :
  1. Composite of pharmacokinetic parameters of ASP015K: tmax, apparent terminal elimination half-life (t1/2), apparent body clearance after oral dosing (CL/F), and apparent volume of distribution (Vz/F) [ Time Frame: Up to Day 15 ]
  2. Composite of pharmacokinetic parameters of ASP015K metabolite H2: Cmax, AUClast, AUCinf, tmax and t1/2 [ Time Frame: Up to Day 15 ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Subject weighs at least 45 kg and has a body mass index (BMI) of 18-32 kg/m2
  • Male subject agrees to sexual abstinence, is surgically sterile or is using a medically acceptable method to prevent pregnancy and agrees to continue using this method until 90 days after the last dose of study drug administration
  • Male subject agrees to not donate sperm until 90 days after the dose of study drug administration
  • Female subject is surgically sterile or is post-menopausal and is not pregnant and is not lactating
  • Subject's 12-lead electrocardiogram (ECG) is normal
  • Subject must be capable of swallowing multiple tablets

Exclusion Criteria:

  • Subject has a previous history of any clinically significant gastro-intestinal, neurological, renal, hepatic, pulmonary, metabolic, cardiovascular, psychiatric, endocrine, hematological disorder or disease, malignancy excluding non-melanoma skin cancer or any other medical condition
  • Subject has had major GI surgery (such as colectomy, cholecystectomy, etc)
  • Subject has a history of consuming more than 14 units of alcoholic beverages per week or has a history of alcoholism or drug/chemical/ substance abuse within past 2 years
  • Subject has/had a symptomatic, viral, bacterial (including upper respiratory infection), or fungal (non-cutaneous) infection within 1 week
  • Subject has a positive test for hepatitis C antibody, or positive test for hepatitis B surface antigen (HBsAg), or positive hepatitis B core antibody
  • Subject has a history of the human immunodeficiency virus (HIV) antibody
  • Subject has a positive tuberculosis (TB) skin test, Quantiferon Gold test or T-SPOT® test
  • Subject received any vaccine within 60 days
  • Subject received an experimental agent within 30 days
  • Subject has an absolute neutrophil count (ANC) < 2500 cells/mm3
  • Subject has had any significant blood loss, donated one unit (450 mL) of blood or more, or received a transfusion of any blood or blood products within 60 days or donated plasma within 7 days
  • Subject has a history of smoking or has used tobacco-containing products and nicotine or nicotine-containing products in the past six months
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01486017

United States, Texas
Dallas, Texas, United States, 75247
Sponsors and Collaborators
Astellas Pharma Inc
Study Director: Medical Director Astellas Pharma Global Development
More Information

Responsible Party: Astellas Pharma Inc
ClinicalTrials.gov Identifier: NCT01486017     History of Changes
Other Study ID Numbers: 015K-CL-PK18
First Posted: December 6, 2011    Key Record Dates
Last Update Posted: December 6, 2011
Last Verified: December 2011

Keywords provided by Astellas Pharma Inc:
healthy subjects
rheumatoid arthritis

Additional relevant MeSH terms:
Vitamin B Complex
Growth Substances
Physiological Effects of Drugs